Home » 2017 » February
Potential Duchenne Muscular Dystrophy therapy from Exonics gets $5m boost

Potential Duchenne Muscular Dystrophy therapy from Exonics gets $5m boost

US based Exonics Therapeutics has secured $5 million seed funding from CureDuchenne Ventures, a subsidiary of nonprofit DMD advocacy group, CureDuchenne to advance its therapy for Duchenne Muscular Dystrophy, a severe form of muscular dystrophy. Headquartered in Boston, Massachusetts, Exonics Therapeutics is a newly founded biotechnology company that develops gene editing technologies such as CRISPR/Cas9. […]

Cyclacel’s blood cancer drug for elderly patients, sapacitabine fails in phase 3 trial

The blood cancer drug for elderly patients, sapacitabine (CYC682) developed by New Jersey based Cyclacel Pharmaceuticals has failed to meet its objective in a crucial phase 3 study. An orally-administered nucleoside analogue, sapacitabine did not meet the primary endpoint which was statistically significant improvement in overall survival (OS) in the phase 3 trial named as […]

Continue reading …
Symic Bio all set to begin peripheral artery disease drug trial

Symic Bio, a California based biopharma focued on matrix biology, is all set to begin the phase 1/2a clinical study named as SHIELD of its peripheral artery disease drug, SB-030. The trial which will be held across multiple sites in Australia and New Zealand will feature 67 patients suffering from symptomatic peripheral artery disease. SHIELD […]

Continue reading …
Novartis lung cancer drug Zykadia gets US FDA priority review

Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions. The expanded use is for metastatic non-small cell lung cancer (NSCLC) patients whose tumors were detected by an approved FDA test […]

Continue reading …
Pfizer’s blood cancer drug inotuzumab ozogamicin gets FDA priority review

Pfizer’s blood cancer drug, inotuzumab ozogamicin has secured a priority review designation from the US Food and Drug Administration (FDA). Inotuzumab ozogamicin has been developed as an anti-CD22 antibody-drug conjugate to treat patients suffering from acute lymphoblastic leukemia (ALL) whether the disease has recurred or in refractory form. As of now, the blood cancer drug […]

Continue reading …
Getting Involved in Preventing Pediatric Medication Errors

Visiting the doctor is not often an enjoyable experience, as it is typically prompted by a health concern or ongoing medical issue which needs addressing. While adults may come to grips with doctor’s visits relatively quickly, for children, interaction with the healthcare system can be overwhelming. This overwhelm creates a situation wherein parents face added […]

Continue reading …
GSK launches OTC allergy relief spray – Flonase Sensimis Allergy Relief in US

GSK Consumer Healthcare has rolled out a new over-the-counter OTC allergy relief spray in the US under the brand name, Flonase Sensimis Allergy Relief which is fluticasone furoate, 27.5 mcg spray. OTC Allergy Relief Spray – Flonase Sensimis Allergy Relief The new GSK allergy nasal spray, Flonase Sensimis Allergy Relief gives relief from seasonal and […]

Continue reading …
Green Tea, the magic potion to treat bone-marrow diseases

Recent studies by the researchers of Washington University of St Louis along with their German collaborators have found that a compound ‘epigallocatechine-3-gallate’ (EGCG) found in green tea leaves help the patients suffering from bone-marrow disorders. Multiple myeloma and amyloidosis which are the life threatening medical complications associated with bone-marrow disorders can be treated with the […]

Continue reading …